Colorectal cancer is on the rise among people aged under 50, contributing to a growing proportion of colorectal cancer cases. Current guidelines for treating colorectal cancer do not distinguish between those diagnosed before 50 (early-onset) and those diagnosed at 50 or later (late-onset). In light of this, there remains uncertainty about how well treatments work for patients with early-onset colorectal cancer.
Prior research suggests that response to EGFR inhibitors may differ between early and late-onset cases, especially for patients with specific characteristics like KRAS wild-type and left-sided metastatic cancer.
This study aims to fill the knowledge gap by using real-world data to elucidate the comparative real-world effectiveness of EGFR inhibitors in patients with early-onset vs late-onset RAS/BRAF wild-type left-sided metastatic colorectal cancer in the United States (US).
Why this matters
This study is crucial as it explores survival outcomes among patients with early- and late-onset metastatic colorectal cancer in a real-world setting. The findings from this research highlights the need for identifying tailored therapeutic strategies based on the unique characteristics of different patient groups in the US and beyond.